TherapeuticsMD (TXMD) Reports In-Line Q4 EPS
Tweet
Share
E-mail
Get Alerts TXMD Hot Sheet
Join SI Premium – FREE
TherapeuticsMD (NASDAQ: TXMD) reported Q4 EPS of ($0.17), in-line with the analyst estimate of ($0.17). Revenue for the quarter came in at $5.09 million versus the consensus estimate of $5 million.
For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Vertex to acquire Crinetics Pharmaceuticals for $10 billion
- Morgan Stanley Resumes Victoria Secret (VSXY) at Overweight
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
